Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Abstract Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin (GEMOX) as first-line therapy for advanced ICC. Thirty patients with pathologically confirmed advanced ICC re...

Full description

Bibliographic Details
Published in:	Signal Transduction and Targeted Therapy
Main Authors:	Guo-Ming Shi, Xiao-Yong Huang, Dong Wu, Hui-Chuan Sun, Fei Liang, Yuan Ji, Yi Chen, Guo-Huan Yang, Jia-Cheng Lu, Xian-Long Meng, Xin-Ying Wang, Lei Sun, Ning-Ling Ge, Xiao-Wu Huang, Shuang-Jian Qiu, Xin-Rong Yang, Qiang Gao, Yi-Feng He, Yang Xu, Jian Sun, Zheng-Gang Ren, Jia Fan, Jian Zhou
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-03-01
Online Access:	https://doi.org/10.1038/s41392-023-01317-7

Similar Items

Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case
by: He-wei Zhang, et al.
Published: (2024-07-01)

Efficacy and safety of R-GemOx regimen for relapsed refractory B-cell lymphoma: a single-arm Meta analysis
by: Guo-Xin HUANG, et al.
Published: (2023-12-01)

Effectiveness and safety of transarterial chemoembolization combined with PD-1 inhibitors and lenvatinib for unresectable intrahepatic cholangiocarcinoma
by: Jin-Tao Huang, et al.
Published: (2025-02-01)

Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma
by: Jia-Cheng Lu, et al.
Published: (2024-01-01)

Hepatic arterial infusion chemotherapy combined with toripalimab and surufatinib for the treatment of advanced intrahepatic cholangiocarcinoma
by: Songlin Song, et al.
Published: (2025-03-01)

Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine
by: Yang Gao, et al.
Published: (2021-07-01)

M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma
by: Long Yang, et al.
Published: (2023-09-01)

Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis
by: Bao-Ye Sun, et al.
Published: (2022-04-01)

The clinical value of regional lymphadenectomy for intrahepatic cholangiocarcinoma
by: Facai Yang, et al.
Published: (2022-01-01)

Mobilization and activation of tumor-infiltrating dendritic cells inhibits lymph node metastasis in intrahepatic cholangiocarcinoma
by: Bao-Ye Sun, et al.
Published: (2024-06-01)

Cystatin B Promotes the Proliferation, Migration, and Invasion of Intrahepatic Cholangiocarcinoma
by: Dai Zhang, et al.
Published: (2025-01-01)

Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report
by: Jun-Wei Zhang, et al.
Published: (2023-03-01)

Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
by: Rongce Zhao, et al.
Published: (2024-05-01)

Efficacy analysis of HAIC combined with lenvatinib plus PD-1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma
by: Zhipeng Lin, et al.
Published: (2024-10-01)

A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma
by: Yinhua Gong, et al.
Published: (2023-05-01)

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
by: Jia-Xin Huang, et al.
Published: (2023-08-01)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
by: Jian Wang, et al.
Published: (2020-10-01)

Proteomic and single-cell landscape reveals novel pathogenic mechanisms of HBV-infected intrahepatic cholangiocarcinoma
by: Yifei Shen, et al.
Published: (2023-02-01)

Lenvatinib inhibits intrahepatic cholangiocarcinoma via Gadd45a-mediated cell cycle arrest
by: Xia Yan, et al.
Published: (2023-02-01)

A case report: deep and durable response to low-dose lenvatinib and tislelizumab in an elderly patient with advanced intrahepatic cholangiocarcinoma
by: Pei Zhang, et al.
Published: (2024-09-01)

Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report
by: Lisha Li, et al.
Published: (2024-12-01)

Case Report: Efficacy of preoperative conversion therapy with lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy in an advanced hepatocellular carcinoma
by: Jing Mao, et al.
Published: (2025-10-01)

A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples
by: Jie Hu, et al.
Published: (2021-03-01)

Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3
by: Jian Zhou, et al.
Published: (2021-03-01)

Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma
by: Meng Sha, et al.
Published: (2019-03-01)

Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma
by: Lin Liu, et al.
Published: (2025-07-01)

Resection of intrahepatic cholangiocarcinoma in octogenarians: a single-center analysis
by: Clara A. Weigle, et al.
Published: (2024-06-01)

Effect of surgical margin width on prognosis in patients with single intrahepatic cholangiocarcinoma from a multicenter study
by: LIU Hongzhi, LIN Ziguo, HUANG Jianlong, ZHOU Weiping, CHENG Zhangjun, LOU Jianying, ZHENG Shuguo, BI Xinyu, WANG Jianming, GUO Wei, LI Fuyu, WANG Jian, ZHENG Yamin, LI Jingdong, CHENG Shi, LIU Jingfeng, ZENG Yongyi
Published: (2021-03-01)

Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial
by: Xun Cao, et al.
Published: (2024-01-01)

Comparison analysis of ICIs and chemotherapy combined with or without lenvatinib as first-line treatment of unresectable intrahepatic cholangiocarcinoma
by: Miao Li, et al.
Published: (2025-03-01)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
by: Chengpei Zhu, et al.
Published: (2023-01-01)

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
by: Zhenyun Yang, et al.
Published: (2024-11-01)

Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma
by: Yu-Hang Ye, et al.
Published: (2024-10-01)

AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/Smad3 pathway
by: Liming Deng, et al.
Published: (2023-09-01)

Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma
by: Xiaoqiang Chai, et al.
Published: (2023-12-01)

Characterization of Immunogenicity of Malignant Cells with Stemness in Intrahepatic Cholangiocarcinoma by Single-Cell RNA Sequencing
by: Jing Bian, et al.
Published: (2022-01-01)

Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma
by: YeXing Huang, et al.
Published: (2024-02-01)

Intrahepatic cholangiocarcinoma
by: A. B. Luk’yanchenko, et al.
Published: (2016-02-01)

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial
by: Yaoping Shi, et al.
Published: (2024-12-01)

Subtype prediction of intrahepatic cholangiocarcinoma using dynamic contrast-enhanced ultrasound
by: Ming-Rui Zhu, et al.
Published: (2024-05-01)